Patient perceptions of the re-usable Respimat® Soft MistTM inhaler in current users and those switching to the device: a real-world, non-interventional COPD study

Michael Dreher* (Corresponding Author), David Price, Asparuh Gardev, Pascale Peeters, Satish Arora, Simone van der Sar-van der Brugge, Richard Dekhuijzen, Omar S Usmani

*Corresponding author for this work

Research output: Contribution to journalArticlepeer-review

1 Citation (Scopus)
5 Downloads (Pure)

Abstract

Objectives
The Respimat® Soft MistTM inhaler (SMI) has recently been improved, with a re-usable device replacing the disposable version. Certain countries are currently phasing out the disposable inhaler. This study aimed to assess patient satisfaction and preference with the re-usable device.
Methods
This 4–6-week, multicentre, open-label, prospective, real-world, non-interventional study was conducted across six European countries. Patients with chronic obstructive pulmonary disease were enrolled between October and December 2019, in three cohorts: (1) currently using the re-usable Respimat SMI; (2) switched from disposable Respimat SMI at study entry; and (3) naïve to any Respimat SMI. Patients were assessed using the Patient Satisfaction and Preference Questionnaire (PASAPQ) and Ease of Handling Questionnaire.
Results
In total, 262 patients were enrolled. At follow-up, the mean PASAPQ score was 83.3/100 overall, with similar results across all three patient cohorts. Most patients were ‘satisfied’ or ‘very satisfied’ with the re-usable device. The overall score for willingness to continue using the device was 87.8/100. In total, 13 adverse events were recorded, none of which was classified as serious.
Discussion
This study provides real-world evidence for practitioners to start patients on Respimat re-usable, irrespective of a patient’s prior experience with this inhaler.
Original languageEnglish
Pages (from-to)1-10
Number of pages10
JournalChronic Respiratory Disease
Volume18
Early online date1 Feb 2021
DOIs
Publication statusPublished - 2021

Keywords

  • COPD
  • Respimat
  • switch
  • preference
  • PASAPQ
  • ease of handling

Fingerprint

Dive into the research topics of 'Patient perceptions of the re-usable Respimat® Soft MistTM inhaler in current users and those switching to the device: a real-world, non-interventional COPD study'. Together they form a unique fingerprint.

Cite this